Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nucor Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Nucor Corporation trades at $270.02 (market cap $61.93B). The key difference: Nucor Corporation is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Nucor Corporation pays a 0.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NUE | |
|---|---|---|
Market Cap | $29.60B | $61.93B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $274.74 |
52-Week Low | $205.48 | $131.78 |
Enterprise Value | $27.56B | $66.34B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Nucor (NUE) trades at $272.28, down 0.85% on the day, as the steel producer shows mixed technical signals with a bullish moving average trend but overbought RSI readings. Fundamentally, the company delivered strong Q2 2026 earnings beats with EPS of $4.84 versus $4.46 expected, while revenue trends show recovery from 2024 lows. Analyst sentiment remains positive with 59% buy ratings and a $279.63 consensus target, though recent tariff developments and cyclical steel demand create headwinds.
The outlook for NUE appears cautiously optimistic with improving earnings momentum and favorable analyst coverage, though investors face risks from steel price volatility and macroeconomic pressures. The stock's current valuation at 21.7x P/E appears reasonable given the earnings recovery trajectory, but requires sustained operational execution to justify further upside beyond current resistance levels near $275.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
